Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more
therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and
anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate
treatment of peginterferon alfa 2a/2b in anti-virus treatment naive patients with HBV related
liver fibrosis.